PARP1 and ovarian cancer: In 2014 the Food and Drug Administration (FDA) approved the first PARP inhibitor, olaparib, for the treatment of BRCA-mutated ovarian cancer and recently designated a breakthrough therapy status for olaparib in BRCA- or ATM-mutated castration-resistant prostate cancer [8, 9].